Funding cutting edge research to wipe out ovarian cancer and save women’s lives.
Why Fund Ovarian Cancer Research
Ovarian cancer is the deadliest gynecological cancer. Most women are diagnosed at advanced stages as there is no early detection test available for women at average risk. The five year survival rate for the disease is 47%. Despite these daunting statistics, ovarian cancer remains underfunded by national funding agencies. The Rivkin Center is committed to supporting cutting-edge research on the prevention, early detection, and treatment of ovarian cancer to improve outcomes for women affected by the disease.
The Rivkin Center’s Scientific Program serves as a catalyst for research by funding the best ideas from all over the world. Our goal is to eradicate ovarian cancer through advances in prevention, early detection, and treatment of the disease. We accomplish this by providing seed funding to researchers globally to develop innovative ideas and by cultivating a strong ovarian cancer workforce.
Together, Rivkin Center awards provide much needed support for ovarian cancer research.
IS ONLY 47%
Latest Science Corner
3 new studies show PARP inhibitors effective at delaying recurrence of disease
for all women with ovarian cancer.